Signal2026-07-17
ClinicalTrials.gov

[PHASE2] Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Part of

Emerging Clinical Immunotherapy And Treatment Trials

Open primary sourceSee the whole picture